Estrogen receptor antagonist

DRUG CLASS:

Estrogen receptor antagonist

News alerts, weekly reports and conference planners

Related drugs:

‹

tamoxifen (107)

OP-1250 (7)

GDC-9545 (4)

Z-endoxifen hydrochloride (2)

tamoxifen (107)

OP-1250 (7)

GDC-9545 (4)

Z-endoxifen hydrochloride (2)

›

No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	tamoxifen Sensitive: A2 - Guideline tamoxifen Sensitive : A2	tamoxifen Sensitive: A2 - Guideline tamoxifen Sensitive : A2
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	tamoxifen Sensitive: A2 - Guideline tamoxifen Sensitive : A2	tamoxifen Sensitive: A2 - Guideline tamoxifen Sensitive : A2
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	tamoxifen Sensitive: A2 - Guideline tamoxifen Sensitive : A2	tamoxifen Sensitive: A2 - Guideline tamoxifen Sensitive : A2
HR positive + HER-2 negative	Male Breast Cancer	HR positive + HER-2 negative	Male Breast Cancer	tamoxifen Sensitive: A2 - Guideline tamoxifen Sensitive : A2	tamoxifen Sensitive: A2 - Guideline tamoxifen Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	tamoxifen Sensitive: A2 - Guideline tamoxifen Sensitive : A2	tamoxifen Sensitive: A2 - Guideline tamoxifen Sensitive : A2
HR positive	Male Breast Cancer	HR positive	Male Breast Cancer	tamoxifen Sensitive: A2 - Guideline tamoxifen Sensitive : A2	tamoxifen Sensitive: A2 - Guideline tamoxifen Sensitive : A2
ER positive	Male Breast Cancer	ER positive	Male Breast Cancer	tamoxifen Sensitive: A2 - Guideline tamoxifen Sensitive : A2	tamoxifen Sensitive: A2 - Guideline tamoxifen Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	tamoxifen + medroxyprogesterone Sensitive: A2 - Guideline tamoxifen + medroxyprogesterone Sensitive : A2	tamoxifen + medroxyprogesterone Sensitive: A2 - Guideline tamoxifen + medroxyprogesterone Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	tamoxifen Sensitive: A2 - Guideline tamoxifen Sensitive : A2	tamoxifen Sensitive: A2 - Guideline tamoxifen Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	tamoxifen + megestrol Sensitive: A2 - Guideline tamoxifen + megestrol Sensitive : A2	tamoxifen + megestrol Sensitive: A2 - Guideline tamoxifen + megestrol Sensitive : A2
ESR1 wild-type + HR positive	HER2 Positive Breast Cancer	ESR1 wild-type + HR positive	HER2 Positive Breast Cancer	tamoxifen Sensitive: A2 - Guideline tamoxifen Sensitive : A2	tamoxifen Sensitive: A2 - Guideline tamoxifen Sensitive : A2
ESR1 mutation + HR positive	HER2 Negative Breast Cancer	ESR1 mutation + HR positive	HER2 Negative Breast Cancer	tamoxifen Sensitive: A2 - Guideline tamoxifen Sensitive : A2	tamoxifen Sensitive: A2 - Guideline tamoxifen Sensitive : A2
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	tamoxifen Sensitive: B - Late Trials tamoxifen Sensitive : B	tamoxifen Sensitive: B - Late Trials tamoxifen Sensitive : B
ANIB1 overexpression	Breast Cancer	ANIB1 overexpression	Breast Cancer	tamoxifen Resistant: B - Late Trials tamoxifen Resistant : B	tamoxifen Resistant: B - Late Trials tamoxifen Resistant : B
TP53 mutation	Breast Cancer	TP53 mutation	Breast Cancer	tamoxifen Resistant: B - Late Trials tamoxifen Resistant : B	tamoxifen Resistant: B - Late Trials tamoxifen Resistant : B
HSD17B2 overexpression	Estrogen Receptor Positive Breast Cancer	HSD17B2 overexpression	Estrogen Receptor Positive Breast Cancer	tamoxifen Sensitive: B - Late Trials tamoxifen Sensitive : B	tamoxifen Sensitive: B - Late Trials tamoxifen Sensitive : B
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	tamoxifen Sensitive: B - Late Trials tamoxifen Sensitive : B	tamoxifen Sensitive: B - Late Trials tamoxifen Sensitive : B
IGFBP7 overexpression	Estrogen Receptor Positive Breast Cancer	IGFBP7 overexpression	Estrogen Receptor Positive Breast Cancer	tamoxifen Sensitive: B - Late Trials tamoxifen Sensitive : B	tamoxifen Sensitive: B - Late Trials tamoxifen Sensitive : B
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	OP-1250 Sensitive: B - Late Trials OP-1250 Sensitive : B	OP-1250 Sensitive: B - Late Trials OP-1250 Sensitive : B
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	Z-endoxifen hydrochloride Sensitive: C2 – Inclusion Criteria Z-endoxifen hydrochloride Sensitive : C2	Z-endoxifen hydrochloride Sensitive: C2 – Inclusion Criteria Z-endoxifen hydrochloride Sensitive : C2
ER mutation	HER2 Negative Breast Cancer	ER mutation	HER2 Negative Breast Cancer	GDC-9545 Sensitive: C2 – Inclusion Criteria GDC-9545 Sensitive : C2	GDC-9545 Sensitive: C2 – Inclusion Criteria GDC-9545 Sensitive : C2
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	tamoxifen Sensitive: C2 – Inclusion Criteria tamoxifen Sensitive : C2	tamoxifen Sensitive: C2 – Inclusion Criteria tamoxifen Sensitive : C2
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	tamoxifen + goserelin acetate Sensitive: C2 – Inclusion Criteria tamoxifen + goserelin acetate Sensitive : C2	tamoxifen + goserelin acetate Sensitive: C2 – Inclusion Criteria tamoxifen + goserelin acetate Sensitive : C2
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	GDC-9545 Sensitive: C2 – Inclusion Criteria GDC-9545 Sensitive : C2	GDC-9545 Sensitive: C2 – Inclusion Criteria GDC-9545 Sensitive : C2
EPRS1 expression	Estrogen Receptor Positive Breast Cancer	EPRS1 expression	Estrogen Receptor Positive Breast Cancer	tamoxifen Sensitive: C3 – Early Trials tamoxifen Sensitive : C3	tamoxifen Sensitive: C3 – Early Trials tamoxifen Sensitive : C3
FTO expression	Estrogen Receptor Positive Breast Cancer	FTO expression	Estrogen Receptor Positive Breast Cancer	tamoxifen Sensitive: C3 – Early Trials tamoxifen Sensitive : C3	tamoxifen Sensitive: C3 – Early Trials tamoxifen Sensitive : C3
CTDSP1 expression	Estrogen Receptor Positive Breast Cancer	CTDSP1 expression	Estrogen Receptor Positive Breast Cancer	tamoxifen Sensitive: C3 – Early Trials tamoxifen Sensitive : C3	tamoxifen Sensitive: C3 – Early Trials tamoxifen Sensitive : C3
BIN3 expression	Estrogen Receptor Positive Breast Cancer	BIN3 expression	Estrogen Receptor Positive Breast Cancer	tamoxifen Sensitive: C3 – Early Trials tamoxifen Sensitive : C3	tamoxifen Sensitive: C3 – Early Trials tamoxifen Sensitive : C3
HR overexpression	Breast Cancer	HR overexpression	Breast Cancer	tamoxifen Sensitive: C3 – Early Trials tamoxifen Sensitive : C3	tamoxifen Sensitive: C3 – Early Trials tamoxifen Sensitive : C3
RSF1 amplification	Estrogen Receptor Positive Breast Cancer	RSF1 amplification	Estrogen Receptor Positive Breast Cancer	tamoxifen Resistant: C3 – Early Trials tamoxifen Resistant : C3	tamoxifen Resistant: C3 – Early Trials tamoxifen Resistant : C3
AURKA overexpression	Estrogen Receptor Positive Breast Cancer	AURKA overexpression	Estrogen Receptor Positive Breast Cancer	tamoxifen Resistant: C3 – Early Trials tamoxifen Resistant : C3	tamoxifen Resistant: C3 – Early Trials tamoxifen Resistant : C3
NOS2 underexpression	Estrogen Receptor Positive Breast Cancer	NOS2 underexpression	Estrogen Receptor Positive Breast Cancer	tamoxifen Sensitive: C3 – Early Trials tamoxifen Sensitive : C3	tamoxifen Sensitive: C3 – Early Trials tamoxifen Sensitive : C3

Estrogen receptor antagonist

Estrogen receptor antagonist

Associations(120)

Associations
(120)